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PENCIRIAN SEL TITIS SKUAMOUS KARSINOMA ORAL CAL 27 
SEBAGAI MODEL UNTUK KAJIAN SEL STEM KANSER 
 
ABSTRAK 
Peratusan sel stem kanser (CSC) agak rendah di kalangan populasi sel barah. 
Oleh itu, langkah-langkah pengasingan dan pengayaan CSC telah menjadi rutin 
bagi kerja-kerja penyelidikan yang melibatkan CSC. CAL 27 (ATCC® CRL-2095 
TM) yang berasal daripada tisu lidah manusia, merupakan salah satu titisan sel 
epitelium skuamus karsinoma yang sering digunakan. Tujuan kajian ini dijalankan 
adalah untuk mewujudkan satu model titisan sel yang bersesuaian untuk mengkaji 
perkembangan CSC secara cekap, dengan mengurangkan masa bagi proses 
pengasingan dan juga langkah pengayaan sel. Kajian dijalankan untuk menentukan 
transformasi morfologi dan juga fisiologi sel titis CAL 27, terutamanya berkenaan 
dengan pengekspresian penanda sel stem mesenkima, tempoh masa penggandaan 
sel, rintangan terhadap rawatan, kebolehbalikan fenotaip, ciri invasif dan keupayaan 
metastatik. Selain itu, penglibatan lekatan sel dan peralihan epitelium-mesenkima 
(EMT), bersama dengan isyarat laluan Wnt juga diselidik. Hasilnya, pemanjangan 
sel CAL 27-O (sel CAL 27 dari generasi ke-6 dan seterusnya) dari sel CAL 27-Y 
(sel CAL 27 sebelum generasi ke-6) dikaitkan dengan peningkatan keupayaan 
invasif dan metastatik, rintangan rawatan yang lebih tinggi, pembalikan fenotaip 
yang mencirikan sel-sel epitelium, selain peningkatan kadar pembaharuan sel. 
Tambahan pula, sel yang mengekspreskan penanda positif sel stem mesenkimia 
(CD105) telah meningkat lebih daripada 70%. Walaubagaimanapun, 
pengekspresian sel dengan protein lekatan sel (CD166) telah menyusut sekurang-
xx 
 
kurangnya 90%, diiringi oleh peningkatan ekspresi vimentin dan penyusutan 
ekspresi E-cadherin untuk EMT. Selain itu, transformasi fenotaip didapati berkaitan 
dengan penyusutan aturan bagi laluan kekutuban sel satah (PCP) Wnt bukan 
kanonikal dalam sel CAL 27-O. Oleh itu, kajian ini boleh digunakan dalam kajian 
berkaitan CSC, untuk memahami perkembangan CSC dan juga untuk proses 
saringan dadah yang berpotensi untuk mensasarkan CSC. 
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CHARACTERIZATION OF CAL 27 ORAL SQUAMOUS CARCINOMA 
CELL LINE AS A MODEL FOR CANCER STEM CELL STUDY 
 
ABSTRACT 
The percentage of cancer stem cells (CSCs) is relatively low in tumour bulk 
population. Therefore, isolation and enrichment steps for CSCs have become 
routine for research works involving CSC. CAL 27 (ATCC® CRL-2095 TM) is one 
of the commonly used squamous epithelial carcinoma cell lines derived from 
human tongue tissue. The present study was conducted with the objective to 
establish a suitable cell line model for studying CSC development efficiently, by 
reducing the time consuming isolation and enrichment steps. Experiments were 
carried out to determine the morphological as well as physiological transformations 
of CAL 27 cell line, particularly on the expression of mesenchymal stem cell 
markers, cell doubling time, treatment resistance, phenotype reversibility, 
invasiveness and metastatic ability. In addition to that, involvement of cell adhesion 
and epithelial-mesenchymal transition (EMT), together with Wnt signaling pathway 
were investigated. As for the results, elongation of CAL 27-O cells (CAL 27 cells 
from 6th passage onwards) from CAL 27-Y cells (CAL 27 cells below 6th passage) 
were found to be associated with enhanced invasive and metastatic capability, 
greater resistance to treatment, reversal of phenotype characterizing epithelial cells, 
besides enhanced proliferation. Moreover, cells expressing mesenchymal stem cell 
positive marker (CD105) was increased for more than 70% with the transition. 
Contrasting to this, cells with cell-cell adhesion protein (CD166) was reduced by 
more than 90%, accompanied by overexpression of vimentin and downregulated 
expression of E-cadherin for EMT. Besides, the phenotypic transformations were 
xxii 
 
associated with downregulation of Wnt noncanonical planar cell polarity (PCP) 
pathway in CAL 27-O cells. Hence, the study could be extended in CSC related 
study, to understand the development of CSCs and also for screening of potential 
drugs targeting CSCs. 
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CHAPTER 1 
INTRODUCTION 
Abnormal growth of cells generates tumours. Benign tumours are not harmful 
to body tissues. Hence, only malignant tumours are cancers. Malignant cancers refer 
to the abnormal growth of cells that damage or destroy normal body tissues. 
Classification of cancer types is based on the types of cell that is initially affected. 
The abnormal growth of cells harms the body as the uncontrollable cell division 
interferes with the digestive, nervous and circulatory systems, except in leukemia 
where cancer prohibits normal blood function. 
 
Oral cancer is the most common site of malignancy in the head and neck 
region that affect lips, tongue, gums, cheeks, sinuses and pharynx. Most of the 
patients with oral cancer are diagnosed at advanced stage that causes therapeutic 
complications with high mortality rate. The factor accountable for the late diagnosis 
is that the early and curable lesions are usually manifested with some common 
symptoms such as swelling lumps, velvety patches, and persistent soreness.  
 
The overall survival rate differs significantly between the carcinoma stages, 
decreases from 75-90% for Stage I to 10-22% for stage IV. High frequency of loco-
regional recurrences is often associated with oral cancer, which is implicated for 
most of the post-surgery and radiotherapy treatment failures. Relapsed oral cancer 
undoubtedly denotes a tough challenge for clinical practitioners due to the 
aggressiveness and invasive behaviours (Da Silva et al., 2012).  
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The time course of relapse manifestation and metastatic progression are 
unpredictable. Currently, chemotherapy remains as the only option of treatment for 
relapsed cancer whenever surgery or re-irradiation is not possible. However, 
development of drug resistance in cancer cells has limited the efficacy of the 
chemotherapy treatment (Da Silva et al., 2012). The high probability of oral cancer 
recurrence is frequently linked to ipsilateral or bilateral lymph node metastasis as the 
extensive lymphatic submucosal network enables the spreading of cancer cells to 
other site in head and neck region (Fan et al., 2011).  
 
Cancer cell populations are heterogeneous in which the self-proliferative 
population is known as cancer stem cell (CSC). According to American Association 
for Cancer Research (AACR), CSCs are defined as a small subset of cancer cells that 
make up a pool of self-sustaining cells with the special ability to self-renew and 
generate heterogeneous lineages of cancer cells (Clarke et al., 2006). CSC population 
was first isolated by Bonnet and Dijk (1997) and Al Hajj (2003) in acute myeloid 
leukemia and solid tumours, respectively. The research obtained attention from many 
researchers ever since then.  
 
Chemotherapy drugs that target the tumour bulk are only able to eliminate the 
chemotherapy sensitive non-CSC, while enriching the chemotherapy-resistant CSC 
and hence worsen the case by promoting recurrence (Frame and Maitland, 2011). 
Characteristics such as high proliferative ability, invasiveness, migration capacity, 
treatment resistance and phenotype reversibility are known to associate with CSCs 
(Reya et al., 2001; Wicha et al., 2006; Sayed et al., 2011; Cabrera et al., 2015; Hong 
et al., 2015). These research findings indicated that CSCs are responsible for cancer 
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recurrence, treatment resistance and metastatic dissemination. The advancement of 
aggressiveness observed from relapsed oral cancer is parallel with the development 
of CSC.  
 
Gioanni and colleagues established two new cell lines from squamous cell 
carcinomas of the tongue in 1982. One of the cell lines that was established was CAL 
27 derived from a 56-year-old Caucasian male. The tumorigenicity of CAL 27 cells 
was confirmed in nude mice during cell line establishment. The cell line was 
established without any genetic manipulation (Gioanni et al., 1988). 
 
Ever since then, CAL 27 cell line was widely used to build oral squamous 
cell carcinoma (OSCC) model for in vitro and in vivo studies, and thus considered as 
a representative cell line for OSCC study (Jiang et al., 2009). Based on CSC 
hypothesis, CSCs in CAL 27 cell line are responsible for the enhanced growth 
regulation, treatment resistance, phenotype plasticity, as well as invasiveness and 
metastatic ability of the cell line. Therefore, CAL 27 cell line was selected for this 
study.  
 
1.1 Problem Statement 
New findings involving CSC have been greatly discussed which brings about 
new ideas and directions for research. However, one of the challenges in CSC 
research is that the percentage of CSC population in tumour bulk is relatively low 
compared to non-CSC (Beck and Blanpain, 2013). Therefore, the process of 
identifying, isolating and enriching CSCs has always been a time-consuming process 
for the study.  Currently, there is no such cellular model available to be used. In view 
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of this, a cellular model mimicking CSC development using currently available cell 
line could be a practical approach for screening study involving CSC. 
 
The first part of this study focused on the morphological transformation of the 
cells, along with detecting and identifying CSC population from the bulk population 
of cells, using appropriate markers. Comparison on mesenchymal stem cell marker 
expression was performed against stem cells from the same region, dental pulp stem 
cells (DPSC). The second part of the study was directed towards characterization of 
the cancer-origin cell line according to CSC properties to recognize the presence and 
transformation of CSC in the cell line. 
  
In the third part of the study, concurrent investigation on epithelial-
mesenchymal transition (EMT) and cell adhesion proteins were done to provide an 
insight on the cellular regulation during CSC development. With these, investigation 
to reveal the missing puzzle on the signaling pathway(s) underlying CSC 
development, particularly related to the transformation of cell line, was performed in 
the last part of the study.  
 
1.2 Rationale of study 
Based on the understanding on CSC concept, identifying CSC from cancer-
origin cell line is feasible. The CSC cellular model would be a more time-effective 
alternative for CSC research by reducing the time requirement for isolating and 
enriching CSCs for fundamental studies, as well as drugs screening. The model could 
be used to predict the development of CSC under defined circumstances created by 
researchers to understand carcinogenesis progression. Furthermore, the cellular 
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model can also be used to evaluate the efficiency of cancer treatment targeting CSC 
specifically.  
 
1.3 Objectives 
The general objective of this project is to establish a better-studied cellular 
model for CSC study by using CAL 27 cell line. In order to achieve the general 
objective, the following detailed objectives are defined: 
 
1. To identify the morphological transformation of CAL 27 cells. 
2. To identify and quantify the mesenchymal stem cell marker CD105 
expressing population among CAL 27 cells.  
3. To characterize cancer stem cell properties exhibited by CAL 27 cells. 
4. To investigate on the protein regulation for cell adhesion and epithelial-
mesenchymal transition (EMT) in CAL 27 cells. 
5. To understand and propose a potential signaling pathway(s) involved in 
early cancer development. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Cancer: The Killer Disease 
Cancer has been so frequent that every one of us would have at least a 
relative or friend that was involved in fighting cancer.  According to the last Health 
Facts 2013 from Ministry of Health (MoH) Malaysia, cancer is one of the top ten 
reasons of hospitalisation and one of the top five causes of death. The most 
frequently encountered cancer types among Malaysians are breast, colorectal and 
lung cancer.  
 
Based on reports from the International Agency for Research on Cancer 
(IARC) Globocan of the World Health Organisation reported by Ferlay et al. (2013), 
one out of 19 Malaysians develops breast cancer, one in 33 develops colorectal 
cancer and one in 40 develops lung cancer. In Malaysia, the number of cancer 
incidence increased from 32,000 new cases in 2008 to about 37,000 in 2012. There 
were only 21,100 cancer mortality in 2008, but the figure has increased to 21,700 
deaths in 2012.  
 
In 2012, 14 million people were diagnosed with cancer worldwide, according 
to the World Cancer Report 2014, a new global cancer report compiled by IARC. 
The striking fact reported in the same report is that cancer has overtaken heart 
disease as the number one killer in 2014. To reduce the number of cases, there is an 
accelerated demand for better understanding on cancer development for the most 
effective and efficient ways to control cancer. 
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2.2 Cancer Progression 
Cancer can begin from any cell in the body. These cells start out as normal 
cells, but then changes with exposure to mutations and become neoplastic. The 
development of cancer is a multistep process in which cells gradually become 
malignant through a progressive series of alterations, indicated by development of 
cancer late in life. Mutations affect how cells grow, work, reproduce and die. They 
may cause the cell to continue growing and dividing uncontrollably instead of dying 
when it is the appropriate timing. Along the expansion of cancer cell population, 
random mutations occur in the individual cells, leading further to divergence in 
molecular identity (Korbel and Campbell, 2013).  
 
The process of cell changes in which a cell loses its capacity to manage its 
rate of division, and thus becomes a cancer cell, is known as cell transformation. 
Although there are many different types of cancer, they all start because of 
uncontrolled and abnormal growth of cells. The cancerous cell generally retains the 
structural and functional characteristics of the normal cell type from which it is 
derived. Almost 80% of all cancers were epithelial cancers from breast, colon, 
prostate and ovary tissues (Diaz-Cano, 2012).  
 
The typical characteristics of cancer are often referred to the poorly 
differentiated phenotype, and the genetic and functional heterogeneity. Within 
tumours, functional heterogeneity was observed as cells exhibited variable 
proliferative and differentiation capacity. While environmental and other non-genetic 
factors are involved in tumorigenesis, it is commonly accepted that cancer occurs 
because of mutations in cancer-susceptible genes namely oncogenes and tumour 
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suppressor genes. Both oncogenes and tumour suppressor genes are gate-keepers in 
cancer initiation (Pizon et al., 2013). 
 
Oncogenes are damaged version of normal genes, the proto-oncogene. These 
proto-oncogenes control various cell functions, particularly in cell growth and 
reproduction. When proto-oncogenes are mutated or activated to turn into oncogenes, 
cells grow out of control and the transformation promotes cancer cell growth. 
Oncogenes have been discovered to take part in different stages of human cancers-
tumour initiation, progression, angiogenesis and metastasis (Shortt and Johnstone, 
2012).  
 
On the other hand, tumour suppressor genes are the genes work to guard 
against cancer. These genes act as barriers that help to stop cell growth and regulate 
cell death such as apoptosis. However, if the tumour suppressor genes are damaged 
or missing, their implementations on cell proliferation and cell death are unchecked. 
Thus, the alteration leads to cancer progression. For example, TP53; the tumour 
suppressor gene that prompts cell death, is often found to be damaged or missing in 
several types of cancer (Kitagishi et al., 2012).   
  
Progressive changes of human cancer from pre-malignant lesions to fully 
malignant invasive tumours have been well recognized from the recorded cases. 
Accumulation of genetic alteration converts pre-malignant cells into more aggressive 
malignant cells, producing primary tumour. At the early stage of primary tumour 
expansion, the cells are not invasive or metastatic. Due to the genetic instability in 
the cells, further genetic alterations occur.  Thus, new clones with invasiveness and 
metastatic capacity are produced, which are the fully malignant cells. However, only 
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a fraction of the cells in primary tumours acquire the invasive and metastatic ability, 
creating heterogeneity in the cell populations (Diaz-Cano, 2012).  
 
2.3 Types of Cancer 
Cancer can begin from abnormal proliferation of any of the cells in the body. 
Therefore, there are more than a hundred distinctive cancer types, which can vary 
considerably in their aggressiveness and response to treatment.  
 
The most noticeable issue in cancer pathology is the difference between 
benign and malignant tumours. A benign tumour remains restricted to its original 
location, but not invading the surrounding normal tissue or spreading to other body 
sites. In contrast, a malignant tumour is capable of both invading surrounding normal 
tissue and spreading throughout the body via the circulatory or lymphatic systems, a 
condition which is known as metastasis. Cancers, which are commonly referring to 
those malignant tumours, are dangerous due to their ability to invade and metastasize. 
Benign tumours can usually be removed by surgery, but the spread of malignant 
tumours to distant body sites often renders effectiveness of localized treatment to 
these tumours (Valastyan and Weinberg, 2011).  
 
Classifications of both benign and malignant tumours are based on the type of 
cell from which they arise. The three main categories for most of the cancer types are 
carcinomas, sarcomas, and leukaemias or lymphomas. Approximately 90% of human 
cancers are carcinomas, developing from epithelial cells. Sarcomas are solid tumours 
of connective tissues such as muscle, bone and cartilage. Leukemias and lymphomas 
arise from the blood-forming cells and from cells of the immune system respectively, 
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occupy approximately 8% of human malignancies. Tumours are further classified 
according to their tissue of origin, for example lung or breast carcinomas (American 
Cancer Society, 2011) 
 
2.4 Oral Carcinoma 
95% of head and neck cancer cases are diagnosed as head and neck squamous 
cell carcinoma (HNSCC) that occur in over half a million people globally. HNSCC is 
the sixth most common malignancy in the world (Sayed et al., 2011). The prognosis 
for patients with recurrent or metastatic HNSCC is generally poor with low 5-year 
survival rates despite treatment advances over the past few decades, with surgery and 
radiation being the core treatment method (Suma et al., 2015).  
 
Approximately half of those diagnosed cases of HNSCC occur specifically in 
the oral cavity, reported as oral squamous cell carcinomas, which might involve lip, 
tongue, gum, cheek, floor of mouth, sinuses and pharynx. The symptoms detected 
such as velvety patches, swelling, lumps or bumps in the oral region with persistent 
soreness can be easily mistaken as other infectious diseases (Tamashiro et al., 2013).  
 
The factors leading to oral cancer include not only alcohol and tobacco that 
were known to be the traditional ones. However, there has been increasing number of 
incidence reported in young patients which are caused by betel quid chewing (Guha 
et al., 2014) and human papillomavirus (HPV). Oral cancer cases developed from 
HPV infection is a factor discovered recently, especially in the United States 
(Martin-Hernan et al., 2013). 
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Despite recent advances in cancer detection and management, most of the 
patients present with late-stage disease because the clinical signs and symptoms of 
head and neck tumours are often nonspecific and tend to be mistaken for other 
common ailments. Consequently, it is essential to search for new biomarkers and 
effective therapy options to optimize cancer treatment (Martinez-Useros and Garcia-
Foncillas, 2015).  
 
2.5 Properties of Cancer Cells 
Losing control over growth, cancerous cells are formed as a result of 
accumulated aberrations that interfere with many of the regulatory mechanisms. With 
the interference from these unregulated mechanisms, the reflected cell behaviour 
display abnormalities in cell proliferation, survival and differentiation that 
distinguish cancer cells from the normal counterparts. These properties serve as a 
characterizing description for cancer cells (Hanahan and Weinberg, 2011).   
 
Cancer cells have reduced requirements for extracellular growth factors as 
compared to normal cells. Proliferation of most of the cells in our body is controlled, 
mostly by polypeptide growth factors. For certain cell types, the availability of serum 
growth factors is the key determinant for their proliferative capacity in culture. This 
property is particularly important in fibroblasts. The requirement for growth factors 
of cancerous cells is closely related to density-dependent inhibition, since the cell 
density is the key determinant for cells to enter quiescent stage (Yang and Xu, 2011).  
 
Cancer cells are able to produce growth factors that stimulate their own 
proliferation in certain cases. Production of growth factors by a cancer cell can lead 
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to continuous autocrine growth stimulation that stimulates cell division in the niches. 
In this condition, cancer cells are less dependent on growth factors from other 
sources. Also, the reduced growth factor dependence of cancer cells is a result from 
aberrations in intracellular signaling systems, such as upregulation or hyperactivity 
of growth factor receptors or other proteins (Ras proteins or protein kinases) (Witsch 
et al., 2010). 
 
Conversely, cancer cells secrete growth factors that promote the formation of 
new blood vessels in angiogenesis. Angiogenesis is needed to support the tumour 
outgrowth that grows beyond the size of normal cells. With increased requirement to 
oxygen and nutrients supply, new blood vessels are formed to support the need. In 
metastasis, the actively growing new capillaries formed are easily penetrated by the 
tumour cells, providing a ready opportunity for cancer cells to enter the circulatory 
system and begin the metastatic process (Witsch et al., 2010). 
 
As illustrated in Figure 2.1, normal cells encounter density-dependant 
inhibition during cell growth. During proliferation, normal cells divide and multiply 
until they reach certain density. The multiplication stops proliferating and arrested in 
G0 stage of cell cycle to remain quiescent. The key distinction between cancer cells 
and normal cells in culture is that the cancer cells are unresponsive to density-
dependent growth inhibition. Cancer cells proceed to continue growing towards high 
cell density in culture, mimicking their uncontrolled proliferation in vivo and in real 
case scenario (Leontieva et al., 2014; Reece et al., 2013).  
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Figure 2.1: Density-dependant inhibition. Normal cells proliferate in culture until 
they reach a finite cell density coming into contact with other cells, at which point 
they become quiescent. Tumour cells, however, continue to proliferate independent 
of cell density. The concepts of ‘contact inhibition of cell proliferation’ and ‘contact 
inhibition of cell movement’ are often taken as two sides of the same coins.   
 (Takai et al., 2008) 
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Cancer cells are not restricted by contact inhibition as opposed to normal 
cells. Normal fibroblasts migrate across the surface of a culture dish until they come 
into contact with a neighbouring cell. Further cell migration is inhibited that causes 
the normal fibroblast cells to adhere to each other, forming an organized arrangement 
of cells on the culture dish surface. Instead, cancer cells continue moving after 
contact with their neighbours, migrating over neighbouring cells. The growth is in a 
disordered, multi-layered pattern. Cancer cells are characteristically insensitive to 
such contact inhibition of growth and movement (Kim and Asthagiri, 2011; Batson et 
al., 2013). 
 
Cancer cells are different from normal cells in their cell-cell and cell-
matrix interactions. Most cancer cells are less adhesive than normal cells, due to 
reduced expression of cell surface adhesion molecules. For example, loss of E-
cadherin in development of carcinomas (epithelial cancers), the key adhesion 
molecule has been observed. As a consequence of reduced expression of cell 
adhesion molecules, cancer cells are able to invade and metastasize to other tissues 
with less restricted interactions with other cells and tissues. The reduced 
adhesiveness of cancer cells also leads to morphological and cytoskeletal alterations 
(Jung et al., 2012). 
 
In the microenvironment, cancer cells exhibit additional properties that 
empower them in invasion and metastasis. Malignant cells secrete proteases that 
digest extracellular matrix components, allowing the cancer cells to invade adjacent 
normal tissues. For instance, secretion of collagenase aids in digestion and 
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penetration of malignant cells through basal laminae to invade underlying connective 
tissue in carcinoma development (Lu et al., 2011; Man et al., 2013).  
 
Most cancer cells display defective differentiation, which is closely related to 
abnormal proliferation. Fully differentiated cells cease cell division or seldom divide. 
Instead of normal differentiation, cancer cells are usually blocked at the stage of 
specialization, corresponding to their continued active proliferation. One of the 
examples to show the relationship between defective differentiation and malignancy 
can be observed in leukaemia. Leukemic cells fail to undergo terminal differentiation 
in generation of erythrocytes, lymphocytes, granulocytes, or macrophages. They 
remained to be at early stages of development at which they retain their ability for 
proliferation (Diaz-Cano, 2012). 
 
In addition to that, many cancer cells fail to undergo apoptosis, the 
programmed cell death. As a result, the life spans of cancer cells are longer in 
comparison to normal cells. Failure of cancer cells to undergo apoptosis enables 
cancer cells to survive in condition deprived of growth factors from environmental 
signals, contrasting the survival of normal cells which rely on signal from growth 
factors or extracellular matrix that prevent apoptosis. Instead of undergoing apoptosis 
with DNA damage, cancer cells fail to correct the situation. Being non-responsive to 
apoptosis, cancer cells become resistant to radiation and chemotherapeutic drugs in 
treatment (Su et al., 2015). 
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2.6 Stem cells at the top of hierarchy 
Stem cells have been a hot topic in biological science. The stem cells are 
unique due to their unlimited regenerative potential to produce more stem cells and 
tissue specific differentiation capacity to differentiate into diverse specialized cell 
types. With more research activities being involved, stem cell technology would be 
the trend for treatment for diseases (Duran and George, 2011).  
 
Categorisation of stem cells can be based on the potency of the cells. 
Totipotent stem cells differentiate into embryonic and extraembryonic cell types to 
give rise to a fully functional organism, as well as to every cell type of the body. 
Pluripotent stem cells are derived from totipotent stem cells, can give rise to almost 
any cell types from any of the three germ layers or any cell types in adult organism. 
Embryonic stem cells are in this category (Horie et al., 2011; Hima and Srilatha, 
2011).  
 
Multipotent stem cells are more differentiated cells, which mean that their 
possible lineages are less variable or more determined. Thus, multipotent stem cells 
are only capable to give rise to a limited number of cells from closely related family. 
Adult hemapoietic stem cells and MSCs are in this category. For example, MSCs 
have been shown to produce bone, muscle, cartilage, fat, and other connective tissues. 
These tissue specific stem cells are indispensable for maintaining tissue homeostasis 
and repair (Hima and Srilatha, 2011). 
 
There are many prospective sources where stem cells can be obtained. 
Embryonic stem (ES) cells are derivatives from the inner cell mass of a blastocyst, 
17 
 
whereas fetal stem cells can be found in fetal organs. Cell therapy using stem cells 
introduce stem cells to targeted site of tissues to treat diseases with or without gene 
therapy. Pluripotent ES cells have been isolated from inner cell mass of early 
embryos for the almost limitless potency in biological research that is able to 
generate mostly all cell types. However, the promising research raised ethical issues, 
leading the development of induced pluripotent stem (iPS) cells. One key drawback 
of stem cell therapy using ES and iPS cells is on their potential for teratoma 
formation, compromising their application in regenerative medicine (Wei et al., 
2013). 
 
Cells have to be replaced even after complete maturation of an organism. 
Adult stem cells have been isolated from various tissues, including central nervous 
system, bone marrow, retina, skeletal muscle and dental pulp (Hima and Srilatha, 
2011; Abdullah et al., 2013). Stem cells play their role in internal repair system in 
most of the tissues, with their capability to divide and replenish damaged cells. The 
new cells after division can be channelled into different differentiation path to 
become more specialized cell types such as muscle cells, red blood cells and white 
blood cells. Hematopoietic stem cells (HSCs) have been widely used for allogeneic 
cell therapy, meaning that the donor is different from the recipient of the cells.  
(Hima and Srilatha, 2011).  
 
With the new hope generated from application of mesenchymal stem cells 
(MSCs) in biomedical field, MSCs catch the attention of scientists for more 
investigations. However, investigations using different isolation and expansion 
methods created ambiguities and inconsistency as it is difficult to compare and 
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contrast study outcomes without a standard method to characterize MSC. To address 
the issue, the Mesenchymal and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy (ISCT) proposed to set the minimal criteria to define 
human MSC (Dominici et al., 2006).  
 
The first criterion being set by ISCT is that the cells must exhibit adherence 
to plastic in standard culture conditions. Secondly, MSC must express CD105, CD73 
and CD90 (≥ 95% of cell population), but not CD45, CD34, CD14 or CD11b, 
CD79α or CD19 and HLA-DR (≤ 2% of cell population). Thirdly, these cells must 
be able to differentiate into osteoblasts, adipocytes and chondroblasts as 
demonstrated by staining of in vitro cell culture. This minimal set of criteria 
standardise a uniform characterization of MSC, so that exchange of data among 
researchers in the field becomes relevant. These criteria, particularly plastic 
adherence and marker expression, were applied in this study for characterizing stem 
cells (Dominici et al., 2006). 
 
Stem cells isolated from adult dental pulp are termed as dental pulp stem cells 
(DPSCs). DPSCs can be collected from dental pulp by means of a non-invasive 
method that can be performed in adults using simple surgical wisdom teeth 
extraction, a routine surgical practice with less ethical issues. DPSCs have been 
studied for the ability to develop into active neurons, osteoblasts precursors, as well 
as chondrogenic and myogenic differentiation potential (Abdullah et al., 2013). In 
this study, DPSCs were used as a comparison control for stem cell characteristics as 
there is a close proximity between DPSCs and oral carcinoma concerning tissue of 
origin, and also concerning debates on ethical issues in stem cells research. 
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On the other hand, stem cells have been used in replenishment of blood and 
immune system suffering from damage during cancer treatment by chemotherapy or 
radiotherapy. Other than immune-reconstitution, stem cells particularly MSCs have 
been reported to be used in cell-based bone reconstitution following chemotherapy 
and surgery in malignancies due to their regeneration and differentiation capacity 
(Suma et al., 2015).  
 
2.7 Stem cells and CSCs 
Scientists and oncologists have been working on a long-standing goal of 
understanding the development of cancer, so that a framework can be established for 
successful treatment. One of the frameworks that attracted much attention is to 
understand cancer as a perturbed mechanism arising from cells in normal tissues that 
retain the tissue specific developmental features (Diaz-Cano, 2012). 
 
Furthermore, analysis on morphology and proliferation of stem cells leads to 
understanding of heterogeneity of stem cell population that not every cell in the 
population actively proliferates at the same time within a given tissue.  With these 
observations in both normal and aberrant tissues, it has been hypothesized that the 
differentiated cells originate from the undifferentiated cells with regenerative ability 
(Beck and Blanpain, 2013).  
 
Former research was led to focus on understanding the genetic changes that 
direct a cell towards aberration in development without considering which cells are 
affected by mutations. The most recent model for carcinogenesis is the “stem cell 
hypothesis”, in which CSCs are the sites of mutations that initiate malignancy. With 
20 
 
this model, cancer has been presented in a hierarchy structure where CSCs are at the 
top of pyramid to perform self-renewal to support on-going tumour growth and 
tissue-specific differentiation (Mannelli and Gallo, 2012; Suma et al., 2015). 
 
In fact, there are diverging opinions on the origin of CSCs. Some researchers 
supported the view that cancers are derived from naïve stem cells that retain self-
renewal ability but accumulated mutations that lead to epigenetic and genetic 
changes for cancer development. On the other side, the opponents stated the 
possibility that CSCs can be derived from differentiated cells that undergo 
dedifferentiation and reactivate the self-propagating activity to cause malignancy 
(Clarke et al., 2006; Van de Stolpe, 2013). 
 
2.8 History of concept development 
The concept started when pathologist Virchow (1855) suggested that tumour 
could be derived from embryonic cells. Following this, Bruce and colleagues (1963) 
showed that only 1-4% of transplanted murine lymphoma cells can form colonies in 
vitro or can initiate a carcinoma in mouse spleen. The concept of cancer cells 
acquired basic features of normal stem-like cells, such as proliferation potential and 
differentiation capacity was proposed by Pierce and Speers (1988).  
 
Previous research by Bonnet and Dick (1997), it was revealed that a single 
leukemic cell that was selected and isolated based on cluster of differentiation 
marker (CD markers) for CSCs, was able to transmit the disease in mouse after 
transplantation. The first solid tumour from which CSCs were identified and isolated 
was from breast cancers by Al-Hajj and colleagues (2003), which were characterized 
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as a CD44high/CD24low subpopulation, and positive for epithelial cell surface antigen. 
The 100 cells being selected using the specific phenotype were able to proliferate and 
form new tumours when transplanted in mice.  
 
With these reports, more research works were initiated and reports on solid 
tumours were consecutively reported, as from Singh et al. (2003) on brain tumour, 
Collins et al. (2005) on prostate cancer, O’Brien et al. (2007) on colon cancer, Li et 
al. (2007) on pancreatic cancer, Quintana et al. (2008) on melanoma, Sell and Leffer 
(2008) on liver cancer. Nevertheless, there are still doubts and criticism over the 
existence of CSCs and their functional role in cancer progression (Maenhaut et al., 
2010). On-going research on CSCs are still being carried out to answer the questions 
that seems to get more complicated with more data accumulating. The postulations 
and deductions on CSCs are reviewed from time to time to be in pace with the latest 
research reports.  
 
2.9 New era of cancer research-the cancer stem cell concept  
Most cancers remain not curable with the currently available therapeutic 
approaches, based on the knowledge that we have learnt about cancer biology in the 
last decades. Current treatments are based on the assumption that cancer is a 
proliferation-based disease. According to this assumption, the main treatments are 
anti-proliferative and they are non-specific and with serious side-effects. Although 
cytotoxic drugs and radiation reduce tumour burden, relapse of the disease occurs in 
the majority of the cases (Pisco and Huang, 2015). 
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At least two models have been proposed to explain heterogeneity in cancer 
cells for the propagating properties and differentiation status: hierarchical cancer 
stem cell model as shown in Figure 2.2 and stochastic model. For each of the model, 
clonal evolution could happen as a result of interaction of microenvironment and 
cells, leading to accumulated epigenetic changes, as demonstrated in Figure 2.3 
(Sayed et al., 2011; Beck and Blanpain, 2013). 
 
Cancer stem cell concept has been derived from understanding on normal 
stem cells. The issue of stem cells has been raised corresponding to cancer 
development. It was found that stem cells and tumour cells exhibit common features 
on their unlimited proliferative and tissue-specific differentiation capacity (Trosko 
and Chang, 1989). The unique replication process in normal tissues allows a stem 
cell to receive signals from the microenvironment to divide and expand the stem cell 
population (Morrison and Kimble, 2006).  
 
According to the cancer stem cell model, a small population of cancer cells 
known as CSCs make up the reservoir of self-sustaining cells with their unique 
properties to propagate and differentiate into the bulk of tumours. CSCs have the 
capacity to divide as well as to expand the cancer stem cell pool and to differentiate 
into the heterogeneous non-tumorigenic cancer cell types to form the bulk of the 
cancer cells within the tumour (Nguyen et al., 2012).  
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Figure 2.2: Hierarchy in tumours. The cellular hierarchy in tumours implies that not 
all cells are equivalent and that only CSCs present long term self-renewal and 
differentiation potential. CSCs give rise to new CSCs, as well as more committed 
progenitors with more restricted renewal potential which eventually produce 
terminally differentiated cells. 
(Beck and Blanpain, 2013) 
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Figure 2.3: Clonal evolution in stochastic and cancer stem cell model 
a. According to stochastic model, all tumour cells are equipotent and randomly 
self-renew to expand the population or differentiate to specific tissue.  
b. With hierarchical CSC model, only a subset of tumour cells has the ability for 
long-term self-renewal and these cells give rise to progenitors with limited 
proliferative potential that eventually terminally differentiate. 
c. Clonal evolution in stochastic model explains that tumour cells transform into 
more aggressive cell type with new somatic mutation. 
d. Clonal evolution in CSC model describes the generation of clonal diversity 
with mutations, which further increase tumour heretogeneity. 
(Beck and Blanpain, 2013) 
  
